{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:00Z","timestamp":1790712540033,"version":"4.1.0"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.phrs.2021.105544","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T23:19:47Z","timestamp":1615677587000},"page":"105544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Ligand decorated biodegradable nanomedicine in the treatment of cancer"],"prefix":"10.1016","volume":"167","author":[{"given":"Ejaj","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-5066","authenticated-orcid":false,"given":"Asgar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza Tamkeen","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nimisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Apurva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta P.","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Real Sumayya Abdul","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep Singh","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105544_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.colsurfb.2014.12.041","article-title":"Nanotechnological carriers for cancer chemotherapy, the state of the art","volume":"126","author":"Estanqueiro","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and cure, a critical analysis","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.phrs.2021.105544_bib3","first-page":"678","article-title":"Targeted anticancer therapy, overexpressed receptors and nanotechnology","volume":"43","author":"Akhtar","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.phrs.2021.105544_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3747\/co.19.994","article-title":"Cancer control: life and death in an unequal world","volume":"19","author":"Sutcliffe","year":"2012","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.phrs.2021.105544_bib5","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.addr.2012.09.036","article-title":"Quantum dots as a platform for nanoparticle drug delivery vehicle design","volume":"65","author":"Probst","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib8","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2021.105544_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","article-title":"Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy","volume":"3","author":"Batist","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2021.105544_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/wnan.1288","article-title":"Nanomedicine: a pharma perspective","volume":"7","author":"Brown","year":"2015","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/17435889.2.4.415","article-title":"Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel","volume":"2","author":"Stinchcombe","year":"2007","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","article-title":"Clinical cancer nanomedicine","volume":"25","author":"Wolfram","year":"2019","journal-title":"Nano Today"},{"issue":"19","key":"10.1016\/j.phrs.2021.105544_bib16","first-page":"30187","article-title":"Implications of nanotechnology for the treatment of cancer: recent advances","author":"Klochkov","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib18","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.2174\/1381612825666190830155319","article-title":"Passive and active drug targeting: role of nanocarriers in rational design of anticancer formulations","volume":"25","author":"Das","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105544_bib19","first-page":"1","article-title":"Analysis of nanoparticle delivery to tumours","volume":"5","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.phrs.2021.105544_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"Perez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2021.105544_bib21","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.2147\/IJN.S165210","article-title":"Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional\/herbal medicines in cancer therapy: a systematic review","volume":"13","author":"Muhamad","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biopha.2018.07.138","article-title":"Ionic gradient liposomes: recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs","volume":"107","author":"Fatima","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/md17080452","article-title":"Conversion of chitin to defined chitosan oligomers: current status and future prospects","volume":"17","author":"Schmitz","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.phrs.2021.105544_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2021.105544_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review","volume":"112","author":"Garces","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2021.105544_bib27","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1039\/b719689j","article-title":"H-A peptide\/protein-polymer conjugates: synthetic strategies and design concepts","volume":"3","author":"Gauthier","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.phrs.2021.105544_bib28","first-page":"1401","article-title":"Dendrimers as nanocarriers for nucleic acid and drug delivery","volume":"22","author":"Mendes","year":"2017","journal-title":"Cancer Ther. Mol."},{"key":"10.1016\/j.phrs.2021.105544_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijpharm.2018.07.030","article-title":"Dendrimers: a versatile nanocarrier for drug delivery and targeting","volume":"548","author":"Sherje","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib30","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.2147\/IJN.S115428","article-title":"CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells","volume":"11","author":"Jiang","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib31","first-page":"1597","article-title":"Multi-functionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells","volume":"2017","author":"Trabulo","year":"1861","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2021.105544_bib32","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1016\/j.biomaterials.2009.07.008","article-title":"Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy","volume":"30","author":"Acharya","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib33","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/22\/3\/035101","article-title":"Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy","volume":"22","author":"Thamake","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.phrs.2021.105544_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10120-015-0471-6","article-title":"Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients","volume":"19","author":"Fuse","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.phrs.2021.105544_bib35","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.2147\/IJN.S143529","article-title":"In vivo evaluation of cetuximab-conjugated poly (\u03b3-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts","volume":"12","author":"Sreeranganathan","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nano.2016.08.017","article-title":"Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer","volume":"13","author":"Bharali","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejpb.2016.08.013","article-title":"Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: in vitro evaluation on 2D and 3D tumor models","volume":"108","author":"Sarisozen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2021.105544_bib38","doi-asserted-by":"crossref","first-page":"778","DOI":"10.7150\/thno.29964","article-title":"Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles","volume":"9","author":"Satpathy","year":"2019","journal-title":"Therano"},{"key":"10.1016\/j.phrs.2021.105544_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700111","article-title":"Panitumumab-conjugated Pt-drug nanomedicine for enhanced efficacy of combination targeted chemotherapy against colorectal cancer","volume":"6","author":"Tsai","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2021.105544_bib40","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/0008-5472.CAN-12-3175","article-title":"A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers11020248","article-title":"Decoration of Anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2021.105544_bib42","doi-asserted-by":"crossref","first-page":"22178","DOI":"10.1039\/C7RA04059H","article-title":"Egf-targeting lipodisks for specific delivery of poorly water-soluble anticancer agents to tumour cells","volume":"7","author":"Ahlgren","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.phrs.2021.105544_bib43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/nano10040783","article-title":"Tumor-targeted delivery of the p53-activating peptide VIP116 with PEG-stabilized lipodisks","volume":"10","author":"Lundsten","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib44","doi-asserted-by":"crossref","first-page":"20261","DOI":"10.1039\/C9NR07257H","article-title":"Repurposing of cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours","volume":"11","author":"McDaid","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.phrs.2021.105544_bib45","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2174\/1381612043383944","article-title":"Cancer-specific ligands identified from screening of peptide-display libraries","volume":"10","author":"Mori","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2021.105544_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/cen-v089n022.p013","article-title":"Improving peptides","volume":"89","author":"Thayer","year":"2011","journal-title":"Chem. Eng. N."},{"key":"10.1016\/j.phrs.2021.105544_bib47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/psc.717","article-title":"Current strategies for the development of peptide based anti-cancer therapeutics","volume":"11","author":"Borghouts","year":"2005","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines4020011","article-title":"Recent innovations in peptide based targeted drug delivery to cancer cell","volume":"4","author":"Gilad","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2021.105544_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(86)90744-0","article-title":"Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin","volume":"46","author":"Tamkun","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105544_bib50","doi-asserted-by":"crossref","first-page":"16792","DOI":"10.1021\/acsami.5b04596","article-title":"Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma","volume":"7","author":"Liu","year":"2015","journal-title":"ACS Appl. Mater. Interface"},{"key":"10.1016\/j.phrs.2021.105544_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","article-title":"Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance","volume":"25","author":"Seguin","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib52","first-page":"7045","article-title":"Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance","volume":"10","author":"Yu","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jconrel.2011.09.070","article-title":"Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues","volume":"157","author":"Kim","year":"2012","journal-title":"J. Cont. Rel."},{"key":"10.1016\/j.phrs.2021.105544_bib54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.biomaterials.2009.11.047","article-title":"Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature","volume":"31","author":"Yu","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2009.10.014","article-title":"LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors","volume":"385","author":"Luo","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01003031","article-title":"Alytesin and bombesin, two peptide analogs from amphibian skin","volume":"269","author":"Anastasi","year":"1971","journal-title":"Naunyn. Schmiede Arch. Pharmakol."},{"key":"10.1016\/j.phrs.2021.105544_bib57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2019.03.005","article-title":"cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo","volume":"301","author":"Gu","year":"2019","journal-title":"J. Cont. Rel."},{"key":"10.1016\/j.phrs.2021.105544_bib58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/10717544.2016.1236849","article-title":"Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer","volume":"24","author":"Yang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib59","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105544_bib60","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2021.105544_bib61","first-page":"2","article-title":"Targeted co-delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer","author":"Li","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.phrs.2021.105544_bib62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.colsurfb.2017.03.058","article-title":"Pep-1 peptide-functionalized liposome to enhance the anticancer efficacy of cilengitide in glioma treatment","volume":"158","author":"Jiao","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/neuonc\/nor141","article-title":"An interleukin 13 receptor 2-specific peptide homes to human Glioblastoma multiforme xenografts","volume":"14","author":"Pandya","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phrs.2021.105544_bib64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biopha.2018.06.137","article-title":"RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy","volume":"106","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib65","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2021.105544_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.actbio.2017.10.013","article-title":"EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo","volume":"64","author":"Fang","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.phrs.2021.105544_bib67","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.2147\/IJN.S141787","article-title":"Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer","volume":"12","author":"Song","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib68","article-title":"Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE2-mediated activation of \u03b2-catenin signaling","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105544_bib69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijpharm.2009.11.014","article-title":"Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro","volume":"386","author":"Zheng","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib70","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1080\/21691401.2019.1615932","article-title":"Development of R 8 modified epirubicin-dihydro-artemisinin liposomes for treatment of non-small-cell lung cancer","volume":"47","author":"Liu","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108614","article-title":"Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine","volume":"112","author":"Hong","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib72","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.2147\/IJN.S192219","article-title":"Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy","volume":"14","author":"Riaz","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12951-015-0116-2","article-title":"A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy","volume":"13","author":"Wang","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/0008-5472.CAN-05-2748","article-title":"Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries","volume":"66","author":"Kolonin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib75","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2014.05.035","article-title":"Prostate cancer relevant antigens and enzymes for targeted drug delivery","volume":"187","author":"Barve","year":"2014","journal-title":"J. Cont. Rel."},{"key":"10.1016\/j.phrs.2021.105544_bib76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1166\/jbn.2015.1910","article-title":"Bombesin encapsulated in long-circulating pH-sensitive liposomes as a radiotracer for breast tumor identification","volume":"11","author":"De Barros","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib77","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3109\/10717544.2015.1099058","article-title":"Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers","volume":"23","author":"Du","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib78","first-page":"7","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2021.105544_bib79","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/ijms18071338","article-title":"Pancreatic ductal adenocarcinoma: current and evolving therapies","volume":"18","author":"Adamska","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat. Rev. Astroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2021.105544_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1245\/s10434-011-1900-3","article-title":"Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades","volume":"19","author":"Winter","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.phrs.2021.105544_bib82","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.biomaterials.2018.11.035","article-title":"Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin","volume":"192","author":"Chen","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib83","doi-asserted-by":"crossref","first-page":"45390","DOI":"10.1021\/acsami.9b15116","article-title":"Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma","volume":"11","author":"Li","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib84","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/1078-0432.CCR-10-0999","article-title":"Plectin-1 as a novel biomarker for pancreatic cancer","volume":"17","author":"Bausch","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050085","article-title":"Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma","volume":"5","author":"Kelly","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.phrs.2021.105544_bib86","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fonc.2013.00084","article-title":"Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer","volume":"3","author":"Konkalmatt","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2021.105544_bib87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heit","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105544_bib88","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.phrs.2018.09.022","article-title":"Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections","volume":"137","author":"Tao","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib90","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.bmcl.2017.06.014","article-title":"Dioscin suppresses TGF-beta1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion","volume":"27","author":"Lim","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105544_bib91","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.2147\/IJN.S194304","article-title":"Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer","volume":"14","author":"Wang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib92","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3109\/10717544.2015.1040527","article-title":"Targeted delivery of transferrin and TAT comodified liposomes encapsulating both paclitaxel and doxorubicin for melanoma","volume":"4","author":"Yuan","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib93","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.addr.2017.05.006","article-title":"Peptide ligand-modified nanomedicines for targeting cells at the tumor micro-environment","volume":"119","author":"David","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib94","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105544_bib95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/glia.10210","article-title":"Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins","volume":"42","author":"Rieger","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2021.105544_bib96","first-page":"1689","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"80","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105544_bib97","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105544_bib98","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2014.49","article-title":"Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1","volume":"110","author":"Akashi","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105544_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijpharm.2006.08.039","article-title":"Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells","volume":"329","author":"Kobayashi","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib100","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.2147\/IJN.S134148","article-title":"iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib101","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ddr.21589","article-title":"iRGD-paclitaxel conjugate nanoparticles for targeted paclitaxel delivery","volume":"80","author":"Hu","year":"2019","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib102","first-page":"291","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"2012","author":"Daniels","year":"1820","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2021.105544_bib103","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","article-title":"Blood\u2013brain barrier transport of therapeutics via receptor mediation","volume":"24","author":"Jones","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2008.08.021","article-title":"Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood\u2013brain barrier (BBB)","volume":"71","author":"Ulbrich","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2021.105544_bib105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.biomaterials.2011.11.012","article-title":"Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles","volume":"33","author":"Xu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib106","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105544_bib107","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23647","article-title":"Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity","volume":"78","author":"Jarvis","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.phrs.2021.105544_bib108","doi-asserted-by":"crossref","first-page":"14925","DOI":"10.18632\/oncotarget.14742","article-title":"Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy","volume":"8","author":"Ruttala","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105544_bib109","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00109-013-1085-2","article-title":"Aptamers: multifunctional molecules for biomedical research","volume":"91","author":"Banerjee","year":"2013","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.phrs.2021.105544_bib110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/v7020751","article-title":"Aptamers in diagnostics and treatment of viral infections","volume":"7","author":"Wandtke","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.phrs.2021.105544_bib111","first-page":"1","article-title":"Aptamers: novel molecules as diagnostic markers in bacterial and viral infections","volume":"2013","author":"Zimbres","year":"2013","journal-title":"BioMed\u00a0Res. Int."},{"key":"10.1016\/j.phrs.2021.105544_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2014.04.055","article-title":"Aptamer binding assays for proteins: the thrombin example-a review","volume":"837","author":"Deng","year":"2014","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.phrs.2021.105544_bib113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17460441.2016.1126244","article-title":"Aptamers: current challenges and future prospects","volume":"11","author":"Rozenblum","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105544_bib114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1367-5931(97)80102-0","article-title":"Aptamers as therapeutic and diagnostic reagents: problems and prospects","volume":"1","author":"Osborne","year":"1997","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.chembiol.2004.10.017","article-title":"Direct in vitro selection of a 2\u2019-O-methyl aptamer to VEGF","volume":"12","author":"Burmeister","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib116","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C","article-title":"Prion-protein-specific aptamer reduces PrPSc formation","volume":"3","author":"Proske","year":"2002","journal-title":"Chembiochem"},{"key":"10.1016\/j.phrs.2021.105544_bib117","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2019-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105544_bib118","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cbpa.2008.06.028","article-title":"SELEX with modified nucleotides","volume":"12","author":"Keefe","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib119","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/ncomms4459","article-title":"2\u2032-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity","volume":"5","author":"Wu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105544_bib120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2012.01.127","article-title":"Properties of an LNA-modified ricin RNA aptamer","volume":"419","author":"Forster","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105544_bib121","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1093\/nar\/gkh862","article-title":"Application of locked nucleic acids to improve aptamer in vivo stability and targeting function","volume":"32","author":"Schmidt","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.105544_bib122","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cbic.200300663","article-title":"Spiegelmers: biostable aptamers. Spiegelmers: biostable aptamers","volume":"4","author":"Eulberg","year":"2003","journal-title":"Chembiochem"},{"key":"10.1016\/j.phrs.2021.105544_bib123","doi-asserted-by":"crossref","first-page":"9474","DOI":"10.1038\/s41598-017-09555-w","article-title":"Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib124","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1039\/C7TB01833A","article-title":"Biomaterials for polynucleotide delivery to anchorage-independent cells","volume":"5","author":"Ansari","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.phrs.2021.105544_bib125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.phrs.2021.105544_bib126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/ijo.2016.3503","article-title":"Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology","volume":"49","author":"Gambari","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2021.105544_bib127","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejps.2016.10.019","article-title":"pH-sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer","volume":"96","author":"Li","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib128","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.18632\/oncotarget.7073","article-title":"Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105544_bib129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.omtn.2016.12.009","article-title":"siRNA-encapsulated hybrid nanoparticles target mutant K-ras and inhibit metastatic tumor burden in a mouse model of lung cancer","volume":"6","author":"Perepelyuk","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2021.105544_bib130","doi-asserted-by":"crossref","first-page":"18496","DOI":"10.3402\/nano.v3i0.18496","article-title":"Utilizing the folate receptor for active targeting of cancer nanotherapeutics","volume":"3","author":"Zwicke","year":"2012","journal-title":"Nano Rev."},{"key":"10.1016\/j.phrs.2021.105544_bib131","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/adhm.201400751","article-title":"Blended nanoparticle system based on miscible structurally similar polymers: a safe, simple, targeted, and surprisingly high efficiency vehicle for cancer therapy","volume":"4","author":"Tao","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2021.105544_bib132","first-page":"1","article-title":"Targeted co-delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer","volume":"13","author":"Yang","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.phrs.2021.105544_bib133","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.nano.2016.06.014","article-title":"Folate-targeted amphiphilic cyclodextrin siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo","volume":"12","author":"Evans","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib134","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/0976-500X.119704","article-title":"Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects","volume":"4","author":"Abidi","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23647","article-title":"Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity","volume":"78","author":"Jarvis","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.phrs.2021.105544_bib136","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJN.S181296","article-title":"Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy","volume":"14","author":"Sun","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"4","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.phrs.2021.105544_bib138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tibtech.2016.07.006","article-title":"Breaking down the barriers to precision cancer nanomedicine","volume":"35","author":"von Roemeling","year":"2017","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib139","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1039\/C5BM00077G","article-title":"Noninvasive theranostic imaging of HSV-TK\/GCV suicide gene therapy in liver cancer by folate targeted quantum dot-based liposomes","volume":"3","author":"Shao","year":"2015","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib140","first-page":"792","article-title":"Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer","volume":"3","author":"Yang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib141","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3109\/10717544.2015.1054052","article-title":"Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy","volume":"23","author":"Zhang","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2014.10.016","article-title":"Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles","volume":"69","author":"Dixit","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib143","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2015.04.028","article-title":"Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics","volume":"489","author":"Li","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib144","doi-asserted-by":"crossref","first-page":"42150","DOI":"10.18632\/oncotarget.6243","article-title":"Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer","volume":"6","author":"He","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105544_bib145","first-page":"1707","article-title":"In vivo pharmacokinetics, bio-distribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle","volume":"23","author":"Rezazadeh","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib146","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijpharm.2017.09.013","article-title":"Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours","volume":"532","author":"Evans","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib147","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.biopha.2018.09.128","article-title":"A novel 5-fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes","volume":"108","author":"Handali","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105544_bib148","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1021\/acsami.5b01685","article-title":"Drug\/dye-loaded, multifunctional PEG-chitosan-iron oxide nanocomposites for methotraxate synergistically self-targeted cancer therapy and dual model imaging","volume":"7","author":"Lin","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib149","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biomaterials.2016.11.040","article-title":"Combination therapy with doxorubicin-loaded galactosylated poly (ethylene glycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer","volume":"116","author":"Singh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2021.105544_bib150","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/onc.2017.145","article-title":"CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma","volume":"36","author":"Zhu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105544_bib151","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S166402","article-title":"Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib","volume":"12","author":"Duan","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib152","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3892\/or.2014.3131","article-title":"Doxorubicin induces drug resistance and expression of the novel CD44st via NF-\u03baB in human breast cancer MCF-7 cells","volume":"31","author":"Fang","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00001703-200402000-00010","article-title":"Biomolecular prognostic factors in breast cancer","volume":"16","author":"Coradini","year":"2004","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2021.105544_bib154","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2147\/DDDT.S202818","article-title":"In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy","volume":"13","author":"Shao","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib155","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105544_bib156","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-319-24223-1_8","article-title":"KRAS-mutant lung cancers in the era of targeted therapy","volume":"893","author":"Naidoo","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib157","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib158","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105544_bib159","doi-asserted-by":"crossref","first-page":"eaal5253","DOI":"10.1126\/scitranslmed.aal5253","article-title":"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS","volume":"9","author":"Ross","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105544_bib160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2019.02.032","article-title":"CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment","volume":"561","author":"Tirella","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib161","doi-asserted-by":"crossref","first-page":"24337","DOI":"10.18632\/oncotarget.15363","article-title":"Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy","volume":"8","author":"Edelman","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105544_bib162","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.2147\/IJN.S203113","article-title":"Antitumor Effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer","volume":"14","author":"Zhang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib163","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cbi.2014.08.003","article-title":"Differential effects of baicalein and its sulfated derivatives in inhibiting proliferation of human breast cancer MCF-7 cells","volume":"221","author":"Wang","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.phrs.2021.105544_bib164","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3892\/mmr.2014.2885","article-title":"Baicalein induces apoptosis of human cervical cancer HeLa cells in vitro","volume":"11","author":"Peng","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3892\/or.2014.3669","article-title":"Baicalein inhibits the invasion of gastric cancer cells by suppressing the activity of the p38 signaling pathway","volume":"33","author":"Yan","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib166","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3389\/fphar.2019.01436","article-title":"Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105544_bib167","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2147\/DDDT.S202818","article-title":"In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy","volume":"13","author":"Shao","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib168","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.2147\/DDDT.S176879","article-title":"Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity","volume":"12","author":"Yang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib169","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1139\/o2012-030","article-title":"Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells","volume":"90","author":"Li","year":"2012","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1179\/joc.2009.21.6.666","article-title":"Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors","volume":"21","author":"Zhu","year":"2009","journal-title":"J. Chemother."},{"key":"10.1016\/j.phrs.2021.105544_bib171","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1742-7843.2012.00921.x","article-title":"Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation","volume":"113","author":"Wang","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2021.105544_bib172","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.2147\/IJN.S201110","article-title":"Hyaluronic acid-decorated redox-sensitive chitosan micelles for tumor-specific intracellular delivery of gambogic acid","volume":"14","author":"Xu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib173","doi-asserted-by":"crossref","first-page":"12762","DOI":"10.1039\/C8CC07858K","article-title":"An oxaliplatin(iv), prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment","volume":"54","author":"Lim","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.phrs.2021.105544_bib174","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1021\/mp5007129","article-title":"Design and function of engineered protein nanocages as a drug delivery system for targeting pancreatic cancer cells via neuropilin-1","volume":"12","author":"Murata","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.actbio.2019.05.034","article-title":"Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo","volume":"92","author":"Wei","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.phrs.2021.105544_bib176","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s11095-016-1884-6","article-title":"Novel water-borne polyurethane nanomicelles for cancer chemotherapy: higher efficiency of folate receptors than trail receptors in a cancerous Balb\/c mouse model","volume":"33","author":"Ajorlou","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib177","first-page":"557","article-title":"PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway","volume":"10","author":"Bao","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib178","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2147\/DDDT.S195832","article-title":"Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation","volume":"13","author":"Bao","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib179","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3892\/or.2017.5345","article-title":"Co-delivery of doxorubicin and ph-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment","volume":"37","author":"Cui","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib180","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/polym11111905","article-title":"Transferrin-conjugated docetaxel-PLGA nanoparticles for tumor targeting: influence on MCF-7 cell cycle","volume":"11","author":"Jose","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.phrs.2021.105544_bib181","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.12.055","article-title":"Anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor","volume":"499","author":"Fitzgerald","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib182","first-page":"4535","article-title":"Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system","volume":"10","author":"Guo","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/cas.14256","article-title":"RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply","volume":"111","author":"Kong","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/pharmaceutics11020063","article-title":"Transferrin-conjugated polymeric nanoparticle for receptor-mediated delivery of doxorubicin in doxorubicin-resistant breast cancer cells","volume":"11","author":"Soe","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2021.105544_bib185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11095-018-2382-9","article-title":"Transferrin-modified vitamin-E\/lipid based polymeric micelles for improved tumor targeting and anticancer effect of curcumin","volume":"35","author":"Muddineti","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib186","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.18632\/oncotarget.2664","article-title":"Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer","volume":"6","author":"McCarroll","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2021.105544_bib187","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.colsurfb.2016.08.059","article-title":"Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells","volume":"148","author":"Nag","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib188","doi-asserted-by":"crossref","first-page":"29461","DOI":"10.1038\/srep29461","article-title":"Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydro-artemisinin conjugate","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib189","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s11095-016-1978-1","article-title":"Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI\/ADR-RES cells in a 3D spheroid model","volume":"33","author":"Pattni","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105544_bib190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ebiom.2018.11.030","article-title":"Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: a unique site for targeted delivery","volume":"38","author":"Bahmani","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib191","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1021\/acs.molpharmaceut.8b00088","article-title":"Multiarm nanoconjugates for cancer cell-targeted delivery of photosensitizers","volume":"15","author":"Zhao","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib192","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10456-007-9088-7","article-title":"Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor","volume":"11","author":"Mousa","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.phrs.2021.105544_bib193","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1210\/en.2005-0102","article-title":"Integrin alpha(v) beta (3) contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis","volume":"146","author":"Bergh","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2021.105544_bib194","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.nucmedbio.2013.08.003","article-title":"Cu-64-Labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis","volume":"40","author":"Kang","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.phrs.2021.105544_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.05.050","article-title":"Synergistic active targeting of dually integrin \u03b1v\u03b23\/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies","volume":"235","author":"Shi","year":"2016","journal-title":"J. Cont. Rel."},{"key":"10.1016\/j.phrs.2021.105544_bib196","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3892\/or.2016.5298","article-title":"Lung cancer gene therapy: transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery","volume":"37","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2021.105544_bib197","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/10717544.2018.1435747","article-title":"Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer","volume":"25","author":"Deshpande","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib198","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10717544.2018.1425777","article-title":"Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide","volume":"25","author":"Lin","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib199","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.colsurfb.2018.09.047","article-title":"Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model","volume":"173","author":"Lakkadwala","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/10717544.2019.1618420","article-title":"Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy","volume":"26","author":"Gong","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib201","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.nano.2015.11.010","article-title":"EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model","volume":"12","author":"Singh","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2013.09.034","article-title":"Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma","volume":"718","author":"Guo","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105544_bib203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/mp300633f","article-title":"Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma","volume":"11","author":"Sawant","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2021.105544_bib204","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.colsurfb.2016.05.037","article-title":"Pharmacokinetics, biodistribution, in vitro cytotoxicity and biocompatibility of Vitamin E TPGS coated trans resveratrol liposomes","volume":"145","author":"Vijayakumar","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib205","article-title":"DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells","volume":"8","author":"Li","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2021.105544_bib206","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","article-title":"Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results","volume":"18","author":"Perez","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"sup3","key":"10.1016\/j.phrs.2021.105544_bib207","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1080\/21691401.2018.1501377","article-title":"Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma","volume":"46","author":"Xiao","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105544_bib208","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1039\/C5SM00464K","article-title":"Tuning assembly and enzymatic degradation of silk\/poly (N-vinyl caprolactam) multilayers via molecular weight and hydrophobicity","volume":"11","author":"Espinosa-Dzib","year":"2015","journal-title":"Soft Matter"},{"key":"10.1016\/j.phrs.2021.105544_bib209","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1021\/am509204u","article-title":"Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against\u00a0prostate cancer","volume":"7","author":"Yang","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/nnm-2018-0321","article-title":"Vitamin B12-conjugated sericin micelles for targeting CD320-overexpressed gastric cancer and reversing drug resistance","volume":"14","author":"Guo","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib211","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10717544.2013.877100","article-title":"Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma","volume":"22","author":"Pandey","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.phrs.2021.105544_bib212","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2147\/DDDT.S238955","article-title":"Targeted therapy for hepatocellular carcinoma: co-delivery of sorafenib and curcumin using lactosylated ph-responsive nanoparticles","volume":"14","author":"Bian","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib213","doi-asserted-by":"crossref","first-page":"15216","DOI":"10.1002\/chem.201603294","article-title":"Tumour-targeted drug delivery with mannose-functionalized nanoparticles self-assembled from amphiphilic \u03b2-cyclodextrins","volume":"22","author":"Ye","year":"2016","journal-title":"Chemistry"},{"key":"10.1016\/j.phrs.2021.105544_bib214","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.colsurfb.2016.05.051","article-title":"Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics","volume":"146","author":"Garg","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jconrel.2010.09.003","article-title":"Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug","volume":"148","author":"Jain","year":"2010","journal-title":"J. Cont. Rel."},{"key":"10.1016\/j.phrs.2021.105544_bib216","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.colsurfb.2015.06.027","article-title":"Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin","volume":"134","author":"Jain","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2021.105544_bib217","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2217\/nnm-2017-0011","article-title":"Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer","volume":"12","author":"Jain","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.phrs.2021.105544_bib218","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/IJN.S226249","article-title":"A NAG-guided nano-delivery system for redox- and pH-triggered intracellularly sequential drug release in cancer cells","volume":"15","author":"Liang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.phrs.2021.105544_bib219","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40169-014-0028-z","article-title":"Transcriptional factor Snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma","volume":"3","author":"Abdulkhalek","year":"2014","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105544_bib220","first-page":"191","article-title":"Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma","volume":"6","author":"Haxho","year":"2014","journal-title":"Breast Cancer Targets Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib221","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.cellsig.2013.08.008","article-title":"A novel epidermal growth factor receptor signaling platform and its targeted translation in pancreatic cancer","volume":"25","author":"Gilmour","year":"2013","journal-title":"Cell Signal."},{"key":"10.1016\/j.phrs.2021.105544_bib222","first-page":"117","article-title":"Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance","volume":"7","author":"O\u2019Shea","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.phrs.2021.105544_bib223","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1039\/C5BM00519A","article-title":"Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform","volume":"4","author":"Kapishon","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.phrs.2021.105544_bib224","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib225","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2012.04.008","article-title":"HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity","volume":"262","author":"Reynolds","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105544_bib227","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ajpath.2013.07.015","article-title":"Single cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients","volume":"183","author":"Onsum","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2021.105544_bib228","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib229","doi-asserted-by":"crossref","first-page":"C975","DOI":"10.1152\/ajpcell.00506.2004","article-title":"Is prostate-specific membrane antigen a multifunctional protein?","volume":"288","author":"Rajasekaran","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phrs.2021.105544_bib230","doi-asserted-by":"crossref","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105544_bib231","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors","volume":"22","author":"Von Hoff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105544_bib232","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp900015y","article-title":"The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic","volume":"6","author":"Davis","year":"2009","journal-title":"Mol. Pharm."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:22:38Z","timestamp":1760912558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":232,"alternative-id":["S1043661821001286"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105544","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ligand decorated biodegradable nanomedicine in the treatment of cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105544"}}